Responses to Hydroxyurea (HU) in PV

PV Chart Survey

A retrospective chart review of patients with PV was conducted in the United States between April and July 2014 to investigate treatment patterns in a real-world setting.1 The study evaluated the prevalence of complete clinicohematologic response (CHR) among those currently receiving HU.2*

Included patients were ≥18 years of age who were alive within prior 6 months, had been diagnosed with PV within the past 3 to 15 years, had received HU therapy for ≥2 months in the past 5 years, had medical record data 12 months pre- and post-HU initiation, and were not a part of PV-related clinical trials.1

A total of 1,309 patient charts were reviewed by 329 hematologic oncologists, medical oncologists, and hematologists.1

Select patient characteristics included1:

  • Mean age, 62.5 years
  • Mean time since diagnosis, 5.2 years
  • 82.5% (1,080/1,309) of patients were treated with HU
    • Mean duration of HU therapy, 47 months
  • 17.5% (229/1,309) of patients discontinued HU therapy

Clinicohematologic response was defined per ELN response criteria as3:

  • Complete: Hct <45% and platelet count ≤400 × 109/L and WBC count ≤10 × 109/L and normal spleen size on imaging and no disease-related symptoms
  • Partial: In patients who do not fulfill the criteria for complete response, Hct <45% without phlebotomy or response in 3 or 4 of the 5 criteria
  • No Response: Any response that does not satisfy partial response
*Study sponsored by Incyte Corporation. Disease-related symptoms: fatigue, pruritus, or headache.
PV chart survey: Among those currently receiving HU, only 37.1% achieved a complete response based on the ELN criteria2,a
chart is shown that depicts the responses among patients currently receiving HU
aELN response criteria are based on the following: Hct level, platelet count, WBC count, spleen size, and disease-related symptoms (microvascular disturbances, pruritus, headache).
PV chart survey: Two-thirds (66.3%) of patients receiving HU (N=1,080) had at least 1 elevated lab value2
chart is shown that depicts the elevated lab values of patients receiving HU
ELN = European LeukemiaNet Hct = hematocrit HU = hydroxyurea PV = polycythemia vera WBC = white blood cell
References

1. Parasuraman S, DiBonaventura M, Reith K, Concialdi K. Blood. 2014;124(suppl;abstr):1852. 2. Parasuraman S, DiBonaventura M, Reith K, Concialdi K. Presented at: 56th ASH® Annual Meeting & Exposition; December 6-9, 2014; San Francisco, CA. Abstract 1852. 3. Barosi G, Birgegard G, Finazzi G, et al. Blood. 2009;113(20):4829-4833.

 
Resources
The potential impact of a target hematocrit level of <45% on major thrombosis or cardiac death.
By: MPN Connect
An animated video highlighting PV pathophysiology and mechanisms of disease.